Psychedelic Lived Experiences Summit - virtual event centering patients and trial participants to bridge science and lived expertise

Psychedelic Lived Experiences Summit centers patient and trial participant lived experience alongside therapists and researchers to bridge science with real world outcomes and limitations. The virtual summit ran over Nov 21-23, 2025, with 50+ speakers and 3,000+ attendees. It included 54 interview recordings and 9 panels, aiming to move beyond “miracle cure” hype and “harm” fear narratives by presenting a full spectrum of experiences from healing to adverse outcomes. A key theme is that clinical trials and policy discussions often miss or underrepresent firsthand expertise, which the summit frames as essential for improving safety, refining treatment expectations, and guiding therapist training and research design. Featured lived-experience speakers describe psychedelic-assisted care involving MDMA, psilocybin, LSD, ketamine, 5-MeO-DMT, and ibogaine (and other psychoactive substances) across PTSD, depression, addiction, and end-of-life or serious illness contexts.